BAYnovation, the randomized clinical trial of a group of 450 patients with adenoviral conjunctivitis, will study the efficacy of the treatment that is the first of its kind worldwide.
The clinical results of BAYnovation are expected in late 2013.
More Articles on Ophthalmology:
Arizona Aiello Eye Institute Expands Services to Foothills Location
LENSAR Laser System Earns FDA 510(k) Clearance
IRIDEX, Peregrine Surgical Partner
